Savara (SVRA) Deferred Taxes (2018)
Savara (SVRA) posted quarterly Deferred Taxes of -$2.5 million for Q4 2018, up 45.07% quarter-over-quarter from -$4.6 million in Q1 2018.
Savara (SVRA) Deferred Taxes (2018) Analysis & Trends
Savara (SVRA) has reported Deferred Taxes for 1 consecutive years, with -$2.5 million the latest figure, recorded in Q4 2018.
- In Q4 2018, Deferred Taxes changed N/A year-over-year to -$2.5 million; the TTM figure through Dec 2018 stood at -$7.1 million (changed N/A YoY), while the FY2018 annual figure was -$7.1 million, down 150.25% from the prior year.
- Deferred Taxes rose to -$2.5 million in Q4 2018 per SVRA's latest filing, from -$4.6 million in the prior quarter.
- Across five years, Deferred Taxes topped out at -$2.5 million in Q4 2018 and bottomed at -$4.6 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -2.50 Mn |
| Mar 31, 2018 | -4.56 Mn |